Sarcoma  >>  Leukine (sargramostim)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Leukine (sargramostim) / Partner Therap
NCT00002995: Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma

Completed
3
483
Europe, Canada, US, RoW
dactinomycin, filgrastim, sargramostim, cyclophosphamide, vincristine sulfate, radiation therapy
Children's Oncology Group, National Cancer Institute (NCI)
Sarcoma
09/06
01/11
NCT00003958: Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma

Completed
3
702
US
dactinomycin, ACT-D, actinomycin C1, AD, Cosmegen, DACT, vincristine sulfate, leurocristine sulfate, VCR, Vincasar PFS, cyclophosphamide, CPM, CTX, Cytoxan, Endoxan, Endoxana, therapeutic conventional surgery, radiation therapy, irradiation, radiotherapy, therapy, radiation, topotecan hydrochloride, hycamptamine, Hycamtin, SKF S-104864-A, TOPO, filgrastim, G-CSF, Neupogen, sargramostim, GM-CSF, Leukine, Prokine, laboratory biomarker analysis
Children's Oncology Group, National Cancer Institute (NCI)
Adult Malignant Mesenchymoma, Adult Rhabdomyosarcoma, Alveolar Childhood Rhabdomyosarcoma, Childhood Malignant Mesenchymoma, Embryonal Childhood Rhabdomyosarcoma, Embryonal-botryoid Childhood Rhabdomyosarcoma, Nonmetastatic Childhood Soft Tissue Sarcoma, Previously Untreated Childhood Rhabdomyosarcoma, Stage I Adult Soft Tissue Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma
10/07
 
NCT01480479 / 2011-006068-32: Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma

Checkmark First Interim data from ACT IV trial in frontline GBM [Trial failed]
May 2016 - May 2016: First Interim data from ACT IV trial in frontline GBM [Trial failed]
Checkmark Second interim analysis of P3 ACT IV trial in front-line GBM [Trial failed]
May 2016 - May 2016: Second interim analysis of P3 ACT IV trial in front-line GBM [Trial failed]
Checkmark From ACT IV trial for front-line GBM at SNO 2016 [Trial failed]
More
Completed
3
745
US, Canada, Europe, RoW
Rindopepimut (CDX-110) with GM-CSF, CDX-110 with sargramostim (GM-CSF) (Leukine®), Temozolomide, Temodar, Temodal, KLH
Celldex Therapeutics
Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma, Glioblastoma With Oligodendroglial Component
11/16
11/16

Download Options